{
    "2018-06-25": [
        [
            {
                "time": "2018-06-25",
                "original_text": "Insider Buying Report: DOVA, ABBV",
                "features": {
                    "keywords": [
                        "Insider Buying",
                        "DOVA",
                        "ABBV"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-25",
                "original_text": "The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Procter & Gamble",
                        "AbbVie",
                        "IBM",
                        "McDonald's",
                        "General Electric"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "consumer goods",
                        "pharmaceuticals",
                        "technology",
                        "food service",
                        "industrial"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-25",
                "original_text": "IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer",
                "features": {
                    "keywords": [
                        "IMBRUVICA",
                        "FDA",
                        "Supplemental New Drug Application",
                        "Waldenström's Macroglobulinemia"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-25",
                "original_text": "The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Procter & Gamble",
                        "AbbVie",
                        "IBM",
                        "McDonald's",
                        "General Electric"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "consumer goods",
                        "pharmaceuticals",
                        "technology",
                        "food service",
                        "industrial"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-25",
                "original_text": "AbbVie and Calibr announce collaboration for next generation T-cell therapies",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Calibr",
                        "collaboration",
                        "T-cell therapies"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}